Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
MMWR Recomm Rep ; 65(2): 1-44, 2016 May 13.
Article in English | MEDLINE | ID: mdl-27172113

ABSTRACT

Tickborne rickettsial diseases continue to cause severe illness and death in otherwise healthy adults and children, despite the availability of low-cost, effective antibacterial therapy. Recognition early in the clinical course is critical because this is the period when antibacterial therapy is most effective. Early signs and symptoms of these illnesses are nonspecific or mimic other illnesses, which can make diagnosis challenging. Previously undescribed tickborne rickettsial diseases continue to be recognized, and since 2004, three additional agents have been described as causes of human disease in the United States: Rickettsia parkeri, Ehrlichia muris-like agent, and Rickettsia species 364D. This report updates the 2006 CDC recommendations on the diagnosis and management of tickborne rickettsial diseases in the United States and includes information on the practical aspects of epidemiology, clinical assessment, treatment, laboratory diagnosis, and prevention of tickborne rickettsial diseases. The CDC Rickettsial Zoonoses Branch, in consultation with external clinical and academic specialists and public health professionals, developed this report to assist health care providers and public health professionals to 1) recognize key epidemiologic features and clinical manifestations of tickborne rickettsial diseases, 2) recognize that doxycycline is the treatment of choice for suspected tickborne rickettsial diseases in adults and children, 3) understand that early empiric antibacterial therapy can prevent severe disease and death, 4) request the appropriate confirmatory diagnostic tests and understand their usefulness and limitations, and 5) report probable and confirmed cases of tickborne rickettsial diseases to public health authorities.


Subject(s)
Rickettsia Infections/diagnosis , Rickettsia Infections/therapy , Tick-Borne Diseases/diagnosis , Tick-Borne Diseases/therapy , Anaplasmosis/diagnosis , Anaplasmosis/epidemiology , Anaplasmosis/therapy , Anti-Bacterial Agents/therapeutic use , Diagnosis, Differential , Doxycycline/therapeutic use , Ehrlichiosis/diagnosis , Ehrlichiosis/epidemiology , Ehrlichiosis/therapy , Humans , Rickettsia Infections/epidemiology , Rocky Mountain Spotted Fever/diagnosis , Rocky Mountain Spotted Fever/epidemiology , Rocky Mountain Spotted Fever/therapy , Tick-Borne Diseases/epidemiology , United States/epidemiology
2.
Clin Infect Dis ; 60(11): 1650-8, 2015 Jun 01.
Article in English | MEDLINE | ID: mdl-25697743

ABSTRACT

BACKGROUND: Rocky Mountain spotted fever (RMSF) has emerged as a significant cause of morbidity and mortality since 2002 on tribal lands in Arizona. The explosive nature of this outbreak and the recognition of an unexpected tick vector, Rhipicephalus sanguineus, prompted an investigation to characterize RMSF in this unique setting and compare RMSF cases to similar illnesses. METHODS: We compared medical records of 205 patients with RMSF and 175 with non-RMSF illnesses that prompted RMSF testing during 2002-2011 from 2 Indian reservations in Arizona. RESULTS: RMSF cases in Arizona occurred year-round and peaked later (July-September) than RMSF cases reported from other US regions. Cases were younger (median age, 11 years) and reported fever and rash less frequently, compared to cases from other US regions. Fever was present in 81% of cases but not significantly different from that in patients with non-RMSF illnesses. Classic laboratory abnormalities such as low sodium and platelet counts had small and subtle differences between cases and patients with non-RMSF illnesses. Imaging studies reflected the variability and complexity of the illness but proved unhelpful in clarifying the early diagnosis. CONCLUSIONS: RMSF epidemiology in this region appears different than RMSF elsewhere in the United States. No specific pattern of signs, symptoms, or laboratory findings occurred with enough frequency to consistently differentiate RMSF from other illnesses. Due to the nonspecific and variable nature of RMSF presentations, clinicians in this region should aggressively treat febrile illnesses and sepsis with doxycycline for suspected RMSF.


Subject(s)
Endemic Diseases , Rocky Mountain Spotted Fever/epidemiology , Rocky Mountain Spotted Fever/pathology , Adolescent , Adult , Aged , Animals , Anti-Bacterial Agents/therapeutic use , Arizona/epidemiology , Child , Child, Preschool , Diagnosis, Differential , Diagnostic Tests, Routine , Doxycycline/therapeutic use , Female , Humans , Infant , Male , Middle Aged , Retrospective Studies , Rocky Mountain Spotted Fever/diagnosis , Rocky Mountain Spotted Fever/drug therapy , Young Adult
3.
Clin Infect Dis ; 60(11): 1659-66, 2015 Jun 01.
Article in English | MEDLINE | ID: mdl-25697742

ABSTRACT

BACKGROUND: Rocky Mountain spotted fever (RMSF) is a disease that now causes significant morbidity and mortality on several American Indian reservations in Arizona. Although the disease is treatable, reported RMSF case fatality rates from this region are high (7%) compared to the rest of the nation (<1%), suggesting a need to identify clinical points for intervention. METHODS: The first 205 cases from this region were reviewed and fatal RMSF cases were compared to nonfatal cases to determine clinical risk factors for fatal outcome. RESULTS: Doxycycline was initiated significantly later in fatal cases (median, day 7) than nonfatal cases (median, day 3), although both groups of case patients presented for care early (median, day 2). Multiple factors increased the risk of doxycycline delay and fatal outcome, such as early symptoms of nausea and diarrhea, history of alcoholism or chronic lung disease, and abnormal laboratory results such as elevated liver aminotransferases. Rash, history of tick bite, thrombocytopenia, and hyponatremia were often absent at initial presentation. CONCLUSIONS: Earlier treatment with doxycycline can decrease morbidity and mortality from RMSF in this region. Recognition of risk factors associated with doxycycline delay and fatal outcome, such as early gastrointestinal symptoms and a history of alcoholism or chronic lung disease, may be useful in guiding early treatment decisions. Healthcare providers should have a low threshold for initiating doxycycline whenever treating febrile or potentially septic patients from tribal lands in Arizona, even if an alternative diagnosis seems more likely and classic findings of RMSF are absent.


Subject(s)
Endemic Diseases , Rocky Mountain Spotted Fever/epidemiology , Rocky Mountain Spotted Fever/pathology , Animals , Female , Humans , Male
4.
J Pediatr ; 166(5): 1246-51, 2015 May.
Article in English | MEDLINE | ID: mdl-25794784

ABSTRACT

OBJECTIVE: To evaluate whether cosmetically relevant dental effects occurred among children who had received doxycycline for treatment of suspected Rocky Mountain spotted fever (RMSF). STUDY DESIGN: Children who lived on an American Indian reservation with high incidence of RMSF were classified as exposed or unexposed to doxycycline, based on medical and pharmacy record abstraction. Licensed, trained dentists examined each child's teeth and evaluated visible staining patterns and enamel hypoplasia. Objective tooth color was evaluated with a spectrophotometer. RESULTS: Fifty-eight children who received an average of 1.8 courses of doxycycline before 8 years of age and who now had exposed permanent teeth erupted were compared with 213 children who had never received doxycycline. No tetracycline-like staining was observed in any of the exposed children's teeth (0/58, 95% CI 0%-5%), and no significant difference in tooth shade (P=.20) or hypoplasia (P=1.0) was found between the 2 groups. CONCLUSIONS: This study failed to demonstrate dental staining, enamel hypoplasia, or tooth color differences among children who received short-term courses of doxycycline at <8 years of age. Healthcare provider confidence in use of doxycycline for suspected RMSF in children may be improved by modifying the drug's label.


Subject(s)
Anti-Bacterial Agents/adverse effects , Dental Enamel/drug effects , Doxycycline/therapeutic use , Rocky Mountain Spotted Fever/drug therapy , Tooth/drug effects , Adolescent , Child , Color , Doxycycline/adverse effects , Humans , Indians, North American , Retrospective Studies , Spectrophotometry , Surveys and Questionnaires
5.
Public Health Rep ; 125(3): 448-56, 2010.
Article in English | MEDLINE | ID: mdl-20433040

ABSTRACT

OBJECTIVE: Streptococcus pneumoniae (S. pneumoniae) causes significant mortality throughout the United States and greater mortality among American Indian/Alaska Natives. Vaccination reduces S. pneumoniae illness. We describe the methods used to achieve the Healthy People 2010 coverage rate goals for adult pneumococcal vaccine among those at high risk for severe disease in this population. METHODS: We implemented a pneumococcal vaccination project to bolster coverage followed by an ongoing multidisciplinary program. We used community, home, inpatient, and outpatient vaccinations without financial barriers together with data improvement, staff and patient education, standing orders, and electronic and printed vaccination reminders. We reviewed local and national coverage rates and queried our electronic database to determine coverage rates. RESULTS: In 2007, pneumococcal vaccination coverage rates among people > or = 65 years of age and among high-risk people aged 18-64 years were 96.0% and 61.2%, respectively, exceeding Healthy People 2010 goals. Government Performance and Results Act analyses reports revealed a 2.7-fold increase (36.0% to 98.0%) of coverage from 2000 to 2007 among people > or = 65 years of age at Whiteriver Service Unit in Whiteriver, Arizona. CONCLUSIONS: We achieved pneumococcal vaccination rates in targeted groups of an American Indian population that reached Healthy People 2010 goals and were higher than rates in other U.S. populations. Our program may be a useful model for other communities attempting to meet Healthy People 2010 goals.


Subject(s)
Healthy People Programs , Immunization Programs , Indians, North American , Outcome Assessment, Health Care , Pneumococcal Infections/prevention & control , Adolescent , Adult , Aged , Arizona , Benchmarking , Health Plan Implementation , Healthy People Programs/organization & administration , Humans , Immunization Programs/organization & administration , Middle Aged , Vaccination/statistics & numerical data
6.
N Engl J Med ; 353(6): 587-94, 2005 Aug 11.
Article in English | MEDLINE | ID: mdl-16093467

ABSTRACT

BACKGROUND: Rocky Mountain spotted fever is a life-threatening, tick-borne disease caused by Rickettsia rickettsii. This disease is rarely reported in Arizona, and the principal vectors, Dermacentor species ticks, are uncommon in the state. From 2002 through 2004, a focus of Rocky Mountain spotted fever was investigated in rural eastern Arizona. METHODS: We obtained blood and tissue specimens from patients with suspected Rocky Mountain spotted fever and ticks from patients' homesites. Serologic, molecular, immunohistochemical, and culture assays were performed to identify the causative agent. On the basis of specific laboratory criteria, patients were classified as having confirmed or probable Rocky Mountain spotted fever infection. RESULTS: A total of 16 patients with Rocky Mountain spotted fever infection (11 with confirmed and 5 with probable infection) were identified. Of these patients, 13 (81 percent) were children 12 years of age or younger, 15 (94 percent) were hospitalized, and 2 (12 percent) died. Dense populations of Rhipicephalus sanguineus ticks were found on dogs and in the yards of patients' homesites. All patients with confirmed Rocky Mountain spotted fever had contact with tick-infested dogs, and four had a reported history of tick bite preceding the illness. R. rickettsii DNA was detected in nonengorged R. sanguineus ticks collected at one home, and R. rickettsii isolates were cultured from these ticks. CONCLUSIONS: This investigation documents the presence of Rocky Mountain spotted fever in eastern Arizona, with common brown dog ticks (R. sanguineus) implicated as a vector of R. rickettsii. The broad distribution of this common tick raises concern about its potential to transmit R. rickettsii in other settings.


Subject(s)
Arachnid Vectors , Rhipicephalus sanguineus/microbiology , Rickettsia rickettsii/isolation & purification , Rocky Mountain Spotted Fever/transmission , Adolescent , Adult , Aged , Animals , Arachnid Vectors/microbiology , Arizona , Child , Child, Preschool , DNA, Bacterial/analysis , Dogs/microbiology , Dogs/parasitology , Female , Humans , Infant , Male , Rickettsia rickettsii/genetics
7.
Am J Trop Med Hyg ; 93(3): 549-551, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26033020

ABSTRACT

Rocky Mountain spotted fever (RMSF) is an emerging public health issue on some American Indian reservations in Arizona. RMSF causes an acute febrile illness that, if untreated, can cause severe illness, permanent sequelae requiring lifelong medical support, and death. We describe costs associated with medical care, loss of productivity, and death among cases of RMSF on two American Indian reservations (estimated population 20,000) between 2002 and 2011. Acute medical costs totaled more than $1.3 million. This study further estimated $181,100 in acute productivity lost due to illness, and $11.6 million in lifetime productivity lost from premature death. Aggregate costs of RMSF cases in Arizona 2002-2011 amounted to $13.2 million. We believe this to be a significant underestimate of the cost of the epidemic, but it underlines the severity of the disease and need for a more comprehensive study.


Subject(s)
Epidemics/economics , Health Care Costs/statistics & numerical data , Rocky Mountain Spotted Fever/economics , Adolescent , Adult , Aged , Arizona/epidemiology , Child , Child, Preschool , Cost of Illness , Epidemics/statistics & numerical data , Female , Humans , Indians, North American/statistics & numerical data , Infant , Male , Middle Aged , Rocky Mountain Spotted Fever/epidemiology , Sick Leave/economics , Young Adult
8.
Emerg Infect Dis ; 8(10): 1029-34, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12396910

ABSTRACT

On October 4, 2001, we confirmed the first bioterrorism-related anthrax case identified in the United States in a resident of Palm Beach County, Florida. Epidemiologic investigation indicated that exposure occurred at the workplace through intentionally contaminated mail. One additional case of inhalational anthrax was identified from the index patient's workplace. Among 1,076 nasal cultures performed to assess exposure, Bacillus anthracis was isolated from a co-worker later confirmed as being infected, as well as from an asymptomatic mail-handler in the same workplace. Environmental cultures for B. anthracis showed contamination at the workplace and six county postal facilities. Environmental and nasal swab cultures were useful epidemiologic tools that helped direct the investigation towards the infection source and transmission vehicle. We identified 1,114 persons at risk and offered antimicrobial prophylaxis.


Subject(s)
Anthrax/diagnosis , Anthrax/transmission , Bioterrorism , Population Surveillance , Anthrax/drug therapy , Anthrax/epidemiology , Antibiotic Prophylaxis , Bacillus anthracis/isolation & purification , Bioterrorism/statistics & numerical data , Environmental Monitoring , Epidemiological Monitoring , Fatal Outcome , Female , Florida/epidemiology , Humans , Inhalation Exposure , Male , Middle Aged , Nasopharynx/microbiology , Risk Factors , Workplace
SELECTION OF CITATIONS
SEARCH DETAIL